Full metadata record

DC Field Value Language
dc.contributor.authorHan, Youngsun-
dc.contributor.authorSengupta, Sandip-
dc.contributor.authorLee, Byung Joo-
dc.contributor.authorCho, Hanna-
dc.contributor.authorKim, Jiknyeo-
dc.contributor.authorChoi, Hwan Geun-
dc.contributor.authorDash, Uttam-
dc.contributor.authorKim, Jin Hyoung-
dc.contributor.authorKim, Nam Doo-
dc.contributor.authorKim, Jeong Hun-
dc.contributor.authorSim, Taebo-
dc.date.accessioned2024-01-19T19:01:54Z-
dc.date.available2024-01-19T19:01:54Z-
dc.date.created2022-01-10-
dc.date.issued2019-10-24-
dc.identifier.issn0022-2623-
dc.identifier.urihttps://pubs.kist.re.kr/handle/201004/119429-
dc.description.abstractWe synthesized 11 novel L-783277 derivatives, in which a structure rigidifying phenyl ring is incorporated into the 14-membered chiral resorcylic acid lactone system. The SAR study with these substances demonstrated that 17 possesses excellent kinase selectivity against a panel of 335 kinases in contrast to L-783277 and inhibits VEGFR3, VEGFR2, and FLT3 with single-digit nanomolar IC50 values. Also, we found that 21, a stereoisomer of 17, has excellent potency (IC50 = 9 nM) against VEGFR3 and selectivity over VEGFR2 and FLT3. 17, a potent dual VEGFR3 and VEGFR2 inhibitor, effectively suppresses both lymphangiogenesis and angiogenesis in a 3D-microfluidic tumor lymphangiogenesis assay and in vivo corneal assay while SAR131675 blocks only lymphangiogenesis. In addition, 17 blocks the endothelial tube formation and suppresses proliferation of PHE tumor vascular model. 17 will be a valuable templatefor developing therapeutically active and selective substances that target both lymphangiogenesis and angiogenesis.-
dc.languageEnglish-
dc.publisherAMER CHEMICAL SOC-
dc.subjectSTEREOSELECTIVE-SYNTHESIS-
dc.subjectINHIBITOR-
dc.subjectPOTENT-
dc.subjectFLT3-
dc.subjectBEVACIZUMAB-
dc.subjectANTITUMOR-
dc.subjectEFFICACY-
dc.subjectRECEPTOR-
dc.subjectESTERS-
dc.subjectMOUSE-
dc.titleIdentification of a Unique Resorcylic Acid Lactone Derivative That Targets Both Lymphangiogenesis and Angiogenesis-
dc.typeArticle-
dc.identifier.doi10.1021/acs.jmedchem.9b01025-
dc.description.journalClass1-
dc.identifier.bibliographicCitationJOURNAL OF MEDICINAL CHEMISTRY, v.62, no.20, pp.9141 - 9160-
dc.citation.titleJOURNAL OF MEDICINAL CHEMISTRY-
dc.citation.volume62-
dc.citation.number20-
dc.citation.startPage9141-
dc.citation.endPage9160-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.identifier.wosid000492801800015-
dc.identifier.scopusid2-s2.0-85073194155-
dc.relation.journalWebOfScienceCategoryChemistry, Medicinal-
dc.relation.journalResearchAreaPharmacology & Pharmacy-
dc.type.docTypeArticle-
dc.subject.keywordPlusSTEREOSELECTIVE-SYNTHESIS-
dc.subject.keywordPlusINHIBITOR-
dc.subject.keywordPlusPOTENT-
dc.subject.keywordPlusFLT3-
dc.subject.keywordPlusBEVACIZUMAB-
dc.subject.keywordPlusANTITUMOR-
dc.subject.keywordPlusEFFICACY-
dc.subject.keywordPlusRECEPTOR-
dc.subject.keywordPlusESTERS-
dc.subject.keywordPlusMOUSE-
Appears in Collections:
KIST Article > 2019
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE